We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AVP Cuts Trauma Transfusion Needs in Half

By HospiMedica International staff writers
Posted on 09 Sep 2019
Giving low-dose arginine vasopressin (AVP) to patients with trauma and hemorrhagic shock cuts the volume of blood products required to stabilize them by half, according to a new study.

Researchers at the University of Pennsylvania (Penn; Philadelphia, PA, USA) and the Cleveland Clinic (CC; OH, USA) conducted a randomized study involving 97 adult trauma patients (18-65 years of age) who received at least six units of any blood product within 12 hours of injury. More...
Participants received either an AVP infusion (49 patients) or placebo (48 patients) for 48 hours in order to maintain a mean arterial blood pressure of at least 65 mm Hg. The aim of the study was to determine whether low-dose supplementation of AVP would decrease the need for transfused blood products during resuscitation.

The results revealed that the patients treated with AVP for 48 hours ended up receiving an average of 1.4 liters of blood products, less than half the average amount given to those treated with the placebo (2.9 liters). The AVP group also had a markedly lower rate (11% versus 34% in the placebo group) of deep-vein thrombosis (DVT). Rates of complications within 30 days for the AVP and placebo groups were otherwise similar, with six deaths in each group. The study was published on August 28, 2019, in JAMA Surgery.

“We can replace a patient's lost blood with blood products such as packed red blood cells, fresh frozen plasma, and platelets, but use of these options can lead to serious complications and they may not fully replace key molecules in blood that are needed to support blood pressure and the normal function of vital organs,” said lead author Carrie Sims, MD, PhD, of the Penn Acute Research Collaboration. “The results of this trial suggest a promising way to reduce the amount of blood needed to save the lives of patients with life-threatening injuries.”

AVP is a hormone synthesized in neurons in the hypothalamus that regulates the tonicity of body fluids. It has two primary functions; first, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons, concentrating urine and reducing urine volume. Second, AVP constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure. AVP released in high concentrations may also raise blood pressure by inducing moderate vasoconstriction.

Related Links:
University of Pennsylvania
Cleveland Clinic


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.